BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17122205)

  • 1. Con: Heparin-bonded cardiopulmonary bypass circuits should be routine for all cardiac surgical procedures.
    Taneja R; Cheng DC
    Anesth Analg; 2006 Dec; 103(6):1370-2. PubMed ID: 17122205
    [No Abstract]   [Full Text] [Related]  

  • 2. Pro: Heparin-coated circuits should be used for cardiopulmonary bypass.
    Jessen ME
    Anesth Analg; 2006 Dec; 103(6):1365-9. PubMed ID: 17122204
    [No Abstract]   [Full Text] [Related]  

  • 3. Pro and con of heparin-bonded circuits for cardiopulmonary bypass.
    Weiss BM; von Segesser LK
    J Cardiothorac Vasc Anesth; 1999 Oct; 13(5):646-52. PubMed ID: 10527241
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass.
    de Vroege R; Huybregts R; van Oeveren W; van Klarenbosch J; Linley G; Mutlu J; Jansen E; Hack E; Eijsman L; Wildevuur C
    Artif Organs; 2005 Jun; 29(6):490-7. PubMed ID: 15926987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More biocompatibility in cardiopulmonary bypass for high-risk patients.
    Baufreton C
    Ann Thorac Surg; 2006 Feb; 81(2):790-1; author reply 791. PubMed ID: 16427917
    [No Abstract]   [Full Text] [Related]  

  • 7. Reoperative sternotomy: minimizing injury without the risks of systemic heparin.
    Singh AK; Stearns G; Maslow A; Feng WC; Schwartz C
    J Thorac Cardiovasc Surg; 2011 Apr; 141(4):1085; author reply 1085. PubMed ID: 21419908
    [No Abstract]   [Full Text] [Related]  

  • 8. Con: heparin-bonded cardiopulmonary bypass circuits do not represent a desirable and cost-effective advance in cardiopulmonary bypass technology.
    Woolf RL; Mythen MG
    J Cardiothorac Vasc Anesth; 1998 Dec; 12(6):710-2. PubMed ID: 9854674
    [No Abstract]   [Full Text] [Related]  

  • 9. Low heparinization and heparin-bonded circuits.
    Hill RC
    Ann Thorac Surg; 1997 Oct; 64(4):1221-2. PubMed ID: 9354574
    [No Abstract]   [Full Text] [Related]  

  • 10. Stroke from heparin-coated circuits and reduced systemic anticoagulation.
    Dewanjee MK
    Ann Thorac Surg; 1997 Oct; 64(4):1218-9. PubMed ID: 9354569
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiopulmonary bypass strategy with low-dose heparin and nafamostat mesilate in cardiac surgery: a safe option for patients with acute stroke.
    Morimoto N; Henmi S; Yoshida M; Mukohara N
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):726-8. PubMed ID: 22541513
    [No Abstract]   [Full Text] [Related]  

  • 12. Pro: heparin-bonded circuits represent a desirable option for cardiopulmonary bypass.
    Shore-Lesserson L
    J Cardiothorac Vasc Anesth; 1998 Dec; 12(6):705-9. PubMed ID: 9854673
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-operative heparin reduces pulmonary microvascular fibrin deposition following cardiac surgery.
    Dixon B; Opeskin K; Stamaratis G; Nixon I; Yi M; Newcomb AE; Rosalion A; Zhang Y; Santamaria JD; Campbell DJ
    Thromb Res; 2011 Jan; 127(1):e27-30. PubMed ID: 20923713
    [No Abstract]   [Full Text] [Related]  

  • 14. Inaccuracy of coagulation studies performed on blood samples obtained from arterial catheter.
    Akinci SB; Salman N; Aykut T; Kanbak M; Aypar U
    J Cardiothorac Vasc Anesth; 2005 Oct; 19(5):702-3. PubMed ID: 16202916
    [No Abstract]   [Full Text] [Related]  

  • 15. Thrombin generation with heparin-bonded cardiopulmonary bypass circuits.
    Bannan S; Martin PG
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):849. PubMed ID: 8800182
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk management in cardiac anesthesia: analysis of critical issues. Introduction.
    Ellison N; Pierce EC
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):1-2. PubMed ID: 9583567
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of heparin-bonded surfaces in cardiopulmonary bypass.
    von Segesser LK
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):200-1. PubMed ID: 11174722
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cardiopulmonary bypass and blood coagulation].
    Kitaguchi K; Furuie H
    Masui; 2001 Dec; 50 Suppl():S115-20. PubMed ID: 11871083
    [No Abstract]   [Full Text] [Related]  

  • 19. Con: low-flow cardiopulmonary bypass is not the preferred technique for patients undergoing cardiac surgical procedures.
    Cook DJ
    J Cardiothorac Vasc Anesth; 2001 Oct; 15(5):652-4. PubMed ID: 11688011
    [No Abstract]   [Full Text] [Related]  

  • 20. Lower dose of heparin for cardiopulmonary bypass is not necessarily associated with lower drainage loss.
    von Heymann C; Krimphove M; Spies C
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):727; author reply 728. PubMed ID: 15784394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.